Epidemiological studies have suggested that diabetes is associated with an increased risk of cancer. However, the underlying molecular mechanism remains unclear. We investigated here whether DNA aptamer directed against advanced glycation end products (AGE-aptamer) inhibited melanoma growth in nude mice. G361 melanoma cells were injected intradermally into the upper flank of athymic nude mice. Mice received continuous intraperitoneal infusion (0.136 mg/day) of either AGE-aptamer (n ¼ 9) or Control-aptamer (n ¼ 8) by an osmotic mini pump. Tumor volume was measured at 4-day interval, and G361 melanoma was excised at day 43 after the aptamer treatment. We further examined the effects of AGE-aptamer on proliferation of AGE-exposed endothelial cells and G361 cells. AGE-aptamer significantly inhibited the in vivo-tumor growth of G361 melanoma. Immunohistochemical and western blotting analyses of G361 melanoma revealed that AGE-aptamer decreased expression levels of proliferating nuclear antigen, CD31 and Mac-3, markers of endothelial cells and macrophages, respectively. AGE-aptamer significantly decreased the number of tumorassociated vessels. AGE, receptor for AGE (RAGE) and vascular endothelial growth factor levels were also reduced in AGE-aptamer-treated G361 melanoma. AGE-aptamer inhibited the AGE-induced proliferation and tube formation of endothelial cells as well as the growth of G361 cells in vitro. The present findings suggest that AGE-aptamer could inhibit the AGE-RAGE axis in G361 melanoma and resultantly suppress the tumor growth in nude mice by blocking the angiogenesis. AGE-aptamer might be a novel therapeutic strategy for preventing the progression of malignant melanoma in diabetes.
Epidemiological studies have suggested that diabetes is associated with an increased risk of various types of cancer. [1] [2] [3] [4] [5] In the Västerbotten Intervention Project of northern Sweden, total cancer risk in women increased with rising plasma levels of fasting and postload glucose, up to a relative risk for the top versus bottom quartile of 1.26 and 1.31, respectively. 1 Risk of cancer of the pancreas, endometrium, urinary tract and of malignant melanoma was statistically significantly associated with high fasting glucose, which was totally independent on age, smoking and body mass index. 1 Although the underling molecular mechanisms remain unclear, a nonenzymatic reaction between reducing sugars and the amino groups of proteins, lipids and nucleic acids may have a role in the increased risk for a variety of cancers in diabetes. The process of glycation has been progressed at an accelerated rate under diabetes, leading to the formation and accumulation of advanced glycation end products (AGE). 6, 7 There is accumulating evidence that interaction of AGE with the receptor for AGE (RAGE) contributes to the development and progression of various age-or diabetes-related disorders, including cardiovascular disease, Alzheimer's disease, osteoporosis, cancer growth and metastasis. [8] [9] [10] [11] Indeed, we, along with others, have previously shown that AGE stimulate growth or migration of pancreatic cancer, lung cancer, malignant melanoma and renal cell carcinoma cells in vitro through the interaction with RAGE. [12] [13] [14] [15] Therefore, the AGE-RAGE axis may be a therapeutic target for slowing the progression of cancers in patients with diabetes.
Among various cancers, malignant melanoma is one of the most highly invasive and metastatic tumors with an incidence and mortality that have been rapidly increasing in recent years. 16, 17 Although therapeutic advances in the treatment of malignant melanoma have been made with anti-cancer drugs and immunotherapy, these therapeutic options may be limited by considerable side effects. 16, 17 Therefore, novel therapeutic strategies that prevent the growth and progression of melanoma are highly desired in patients with diabetes.
Aptamers are short, single-stranded DNA or RNA molecules that can bind with high affinity and specificity to a wide range of target proteins. 18 Numerous aptamers have been developed and used in the clinical fields as a tool for modulating the function of various proteins. 19, 20 Pegaptanib, an RNA aptamer directed against vascular endothelial growth factor 165 (VEGF 165 ) isoform, has been shown to be effective in treating choroidal neovascularization in patients with agerelated macular degeneration. 19 We have recently found that high-affinity DNA aptamer directed against AGE (AGEaptamer) blocks the progression of diabetic nephropathy in an animal model of obese and type 2 diabetes. 21 Therefore, in this study, we examined whether and how AGE-aptamer could inhibit growth of G361 cells, human malignant melanoma cells, in nude mice. We further investigated the effects of AGE-aptamer on AGE-induced proliferation of G361 and human endothelial cells in vitro.
METHODS AND METHODS Materials
Bovine serum albumin (BSA) (essentially fatty acid free and essentially globulin free, lyophilized powder) was purchased from Sigma (St Louis, MO, USA). D-glyceraldehyde was purchased from Nakalai Tesque (Kyoto, Japan).
Screening and Modification of AGE-Aptamer (Systematic Evolution of Ligands by EXponential enrichment (SELEX))
Preparation and selection of DNA aptamers were performed as described previously. 21 Sequences of AGE-aptamer and control DNA aptamer (Control-aptamer) are as below. AGEaptamer; 5 0 -CCGAAACCAGACCACCCCACCAAGGCCACT CGGTCGAACCGCCAACACTCACCCCA-3 0 , and Controlaptamer; 5 0 -GTTATCTGTCATAGGAACAGTCAGACTCAG CGTCGCAGTTCAGGGCACTTTAGCAC-3 0 . DNA aptamers are susceptible to degradation by nucleases. 21 This will limit their applications for real samples, such as blood and tissues. To solve this issue, we modified aptamers with phosphorothioate as described previously. 21 We confirmed that AGEaptamer, but not Control-aptamer, bound to AGE-modified human serum albumin with a dissociation constant of 1.38 Â 10 À 6 M.
Growth of G361 Melanoma in Nude Mice
Two million G361 cells were injected intradermally into the upper flank of 6-week-old female athymic nude mice (Japan Clea, Tokyo, Japan; n ¼ 17). 14 Mice received continuous intraperitoneal infusion (0.136 mg/day) of either AGEaptamer (n ¼ 9) or Control-aptamer (n ¼ 8) by an osmotic mini pump (Alzet osmotic pumps, model 1004, Cupertino, CA, USA) and were maintained under specific pathogen-free conditions as described previously. 21 Later, the smallest and largest diameters of tumors were measured at 4-day interval with a digital caliper, and tumor volumes were calculated using the following formula: volume (mm 3 
2 Â (largest diameter))/2 as described previously. 14 Forty-three days after the continuous intraperitoneal infusion of each aptamer, G361 melanoma was excised for immunohistochemical and western blotting analyses. All experimental procedures were conducted in accordance with the National Institutes Health Guide for Care and Use of Laboratory Animals and were approved by the ethnical committee of Kurume University School of Medicine.
Immunohistochemical Analysis
Specimens of G361 melanoma were fixed with 4% paraformaldehyde, embedded in paraffin, sectioned at 4-mm intervals and mounted on glass slides. The sections were incubated in 0.3% hydrogen peroxide methanol for 30 min to block endogenous peroxidase activity and incubated overnight at 4 1C with antibodies (Abs) raised against proliferation cell nuclear antigen (PCNA) (Abcam, Cambridge, United Kingdom), CD31 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), Mac-3 (Santa Cruz Biotechnology), AGE, RAGE (Santa Cruz Biotechnology) and VEGF (Santa Cruz Biotechnology) as described previously. 22 Then the reactions were visualized with a Histofine Simple Stain Mouse MAX-PO kit (Nichirei, Tokyo, Japan). Immunoreactivity of each sample was measured by microcomputer-assisted ImageJ.
Western Blotting Analysis
Twenty micrograms of proteins were extracted from G361 melanoma with lysis buffer, and then separated by SDS-PAGE and transferred to nitrocellulose membranes as described previously. 23 Membranes were probed with Abs against PCNA, CD31, lysosomal-associated membrane protein 2 (Mac-3) (Abcam), AGE, RAGE, VEGF, a-tubulin (Santa Cruz Biotechnology) or b-actin (Santa Cruz Biotechnology), and then immune complexes were visualized with an enhanced chemiluminescence detection system (Amersham Bioscience, Buckinghamshire, United Kingdom).
Preparation of AGE-BSA AGE-BSA was prepared as described previously. 24 In brief, BSA (25 mg/ml) was incubated under sterile conditions with 0.1 M glyceraldehyde in 0.2 M NaPO 4 buffer (pH 7.4) for 7 days. Then unincorporated sugars were removed by PD-10 column chromatography and dialysis against phosphate-buffered saline. Control non-glycated BSA was incubated in the same conditions except for the absence of reducing sugars. Preparations were tested for endotoxin using Endospecy ES-20S system (Seikagaku, Tokyo, Japan); no endotoxin was detectable.
Assay of Tumor-Associated Angiogenesis
After two million G361 cells were injected intradermally into athymic nude mice, mice received continuous intraperitoneal infusion of either AGE-aptamer (n ¼ 9) or Control-aptamer (n ¼ 8) as described above. On day 43 after the procedure, tumors were excised, and tumor-associated angiogenesis was quantitated by counting the number of vessels in G361 melanoma cells according to the method described by Murata et al. 25 Preparation of Ab Raised Against Human RAGE (RAGEAb) RAGE-Ab, which recognizes the amino-acid residues 167-180 of human RAGE protein, was prepared and used for neutralizing assays as described previously. 26 G361 Cells G361 cells (American Type Culture Collection, Manassas, VA, USA) were maintained in Dulbecco's modified Eagle's medium (DMEM) (Sigma) supplemented with 10% fetal bovine serum (FBS). G361 cells in DMEM containing 1% FBS were treated with 1000 mg/ml AGE-BSA or non-glycated BSA for 24 h in the presence or absence of 2 mM AGE-aptamer or Control-aptamer.
Human Umbilical Vein Endothelial Cells (HUVEC)
HUVEC were cultured in endothelial basal medium supplemented with 2% FBS, 0.4% bovine brain extracts, 10 ng/ml human epidermal growth factor and 1 mg/ml hydrocortisone according to the supplier's instructions (Clonetics, San Diego, CA, USA). HUVEC were treated with 100 mg/ml AGE-BSA or non-glycated BSA for 24 h in the presence or absence of 2 mM AGE-aptamer, 2 mM Control-aptamer or 5 mg/ml RAGE-Ab. Cell proliferation experiments were carried out in a medium lacking epidermal growth factor and hydrocortisone (assay medium).
Cell Proliferation Assay
Cell proliferation levels were measured with an electron coupling reagent WST-1-based colorimetric assay according to the supplier's recommendations (Roche Applied Science, Indianapolis, IN, USA).
Tube Formation In Vitro Assay medium was incubated with 100 mg/ml non-glycated BSA or AGE-BSA in the presence or absence of 2 mM AGE-aptamer or Control-aptamer at 37 1C for 2 h. Then HUVEC (1 Â 104 cells) were seeded on BD Biocoat Cellware Matrigel Basement Membrane Matrix 48-well Plates (BD Bioscience, Franklin Lakes, NJ, USA) and incubated in the pretreated assay medium. After 3 h, three microscopic fields selected at random from each well (N ¼ 3) were photographed, and the lengths of tube-like structures were measured with a microcomputer-assisted ImageJ as described previously. 27 
Statistical Analysis
All values were presented as means ± s.e. One-way ANOVA followed by the Scheffe's F test or Student's t test was performed for statistical comparisons; Po0.05 was considered significant.
RESULTS

Effects of AGE-Aptamer on Tumor Growth in Nude Mice
We first investigated whether continuous infusion of AGEaptamer could inhibit melanoma growth in nude mice. G361 melanoma cells formed rapidly growing tumors in nude mice, reaching 400-500 mm 3 after 43 days. In contrast, continuous intraperitoneal injection of AGE-aptamer significantly inhibited the in vivo tumor growth of G361 melanoma over an observation period of up to 43 days (Figure 1 ).
Effects of AGE-Aptamer on PCNA, CD31, TumorAssociated Angiogenesis and Mac-3 Levels in G361 Melanoma Immunohistochemical detection of proliferating cells revealed that ratio of PCNA-positive cell nuclei to total cell nuclei was lower in AGE-aptamer-treated G361 melanoma (Figure 2a) . Furthermore, compared with Control-aptamer-treated mice, PCNA levels in G361 melanoma of AGE-aptamer-treated mice were significantly decreased (Figure 2a) . However, apoptotic cell death of G361 melanoma was not increased by the treatment of AGE-aptamer (data not shown).
Tumor-associated angiogenesis and macrophage infiltration have been known to contribute to tumor growth and expansion in vivo. 28, 29 Furthermore, VEGF not only has a crucial role in tumor angiogenesis and expansion but it could also evoke inflammatory reactions in tumors. [30] [31] [32] [33] [34] [35] As we have previously shown that VEGF is induced by engagement of RAGE with AGE, 24, 26 we studied the effects of AGE-aptamer on angiogenesis and macrophage infiltration in G361 melanoma and then investigated the involvement of AGE-RAGE-VEGF axis in anti-tumor actions of aptamer. For this, we first examined the effects of AGE-aptamer on expression levels of CD31 and Mac-3, markers of capillary endothelial cells and macrophages, respectively. 30 Immunohistochemical and western blotting analyses revealed that AGE-aptamer treatment significantly suppressed angiogenesis and macrophage infiltration in the tumors of nude mice (Figures 2b and d) . Furthermore, AGE-aptamer significantly decreased the number of tumor-associated vessels (Figure 2c ).
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Effects of AGE-Aptamer on Expression Levels of AGE, RAGE and VEGF in G361 Melanoma
We next examined the AGE, RAGE and VEGF expression levels in the tumors. Both AGE-modified proteins and their receptor RAGE expression in G361 melanoma were significantly decreased by the treatment of AGE-aptamer. Moreover, compared with Control-aptamer, continuous administration of AGE-aptamer significantly suppressed VEGF expression levels in G361 melanoma as well (Figures 3a-c) .
Effects of AGE-Aptamer on Proliferation and Tube Formation of HUVEC As shown in Figure 4a , AGE significantly increased proliferation of HUVEC, which was blocked by the treatment of AGE-aptamer or RAGE-Ab. Furthermore, AGE-aptamer, but not Control-aptamer, significantly blocked the AGE-induced increase in tube formation of HUVEC in vitro (Figure 4b ).
Effects of AGE-Aptamer on Proliferation of G361 Cells
As shown in Figure 4c , AGE significantly increased proliferation of G361 melanoma cells in vitro, which was completely prevented by the treatment with AGE-aptamer.
DISCUSSION
In this study, we have found for the first time that (1) longterm continuous intraperitoneal injection of AGE-aptamer inhibits the in vivo-tumor growth of G361 melanoma in nude mice, (2) number of proliferating cells in G361 melanoma is significantly decreased by the treatment of AGE-aptamer, whereas AGE-aptamer does not affect apoptotic cell death of tumor cells, (3) AGE-aptamer significantly suppresses tumorassociated angiogenesis in nude mice, (4) AGE-aptamer significantly decrease expression levels of AGE, RAGE and VEGF in G361 melanoma, (5) AGE stimulate the growth and tube formation of HUVEC, both of which are significantly inhibited by the treatment of AGE-aptamer, but not Controlaptamer, and (6) AGE-aptamer completely prevents the AGE-induced G361 melanoma cell proliferation in vitro. These observations demonstrate that AGE-aptamer might inhibit the AGE-RAGE axis in G361 melanoma and resultantly suppress the tumor growth in nude mice by blocking the angiogenesis. Given the accelerated formation and accumulation of AGE in diabetes, 6,7 our present findings suggest that AGE-aptamer might be a novel therapeutic strategy for preventing the progression of malignant melanoma in diabetes. 
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Several lines of evidence implicate VEGF as the key angiogenic factor involved in melanoma growth and metastasis. [30] [31] [32] [33] Furthermore, VEGF acts as a pro-inflammatory cytokine; it could induce macrophage infiltration into tumors as well. 34, 35 Indeed, VEGF expression levels are associated with angiogenesis and macrophage infiltration, the extent of which being correlated with melanoma prognosis. [30] [31] [32] [33] Therefore, our present study suggests that AGEaptamer might inhibit tumor-associated angiogenesis and macrophage infiltration by blocking the VEGF expression in G361 melanoma.
We have previously shown that the AGE-RAGE interaction stimulates growth and tube formation of endothelial cells through the autocrine production of VEGF. 36 Moreover, AGE also induce VEGF expression in tumor cells via the interaction with RAGE. 26, 37 In this study, expression levels of AGE, RAGE and VEGF were suppressed mainly in tumor cells. So, blockade of the AGE-RAGE axis by AGE-aptamer in G361 tumor cells might contribute to the suppression of VEGF expression. However, involvement of other cell types cannot be totally ruled out.
We have very recently found that AGE-aptamer used here not only inhibits the binding of AGE to RAGE and subsequently suppresses its downstream signaling in vitro but could also accelerate the degradation rate of AGE and reduce their accumulation in diabetic mice. 21 As AGE-RAGE interaction induces RAGE expression in a variety of cells, which could promote the formation of AGE again, 8, 9 AGEaptamer may reduce both AGE and RAGE expression in G361 melanoma by blocking the positive feedback loop between AGE and RAGE axis.
In this study, as the case in HUVEC, AGE-aptamer inhibited the proliferation of AGE-exposed G361 cells in vitro. Furthermore, we have previously shown that AGE-aptamer and melanoma A Ojima et al RAGE-Ab completely inhibits the AGE-induced proliferation of G361 cells in vitro. 14 Therefore, AGE-aptamer might partly work as an anti-melanoma agent by directly acting on G361 melanoma cells. In support of this speculation, we have previously shown that AGE-RAGE interaction stimulates the growth of cultured breast cancer cells. 26 Effects of AGE-aptamer on HUVEC and G361 cell proliferation. (a) HUVEC were treated with 100 mg/ml AGE-BSA or non-glycated BSA for 24 h in the presence or absence of 2 mM AGE-aptamer, 2 mM Control-aptamer or 5 mg/ml RAGE-Ab. (b) Assay medium was incubated with 100 mg/ml nonglycated BSA or AGE-BSA in the presence or absence of 2 mM AGE-aptamer or Control-aptamer at 37 1C for 2 h. Then HUVEC were seeded on Matrigelcoated wells and incubated in the pretreated assay medium. After 3 h, nine microscopic fields selected at random were photographed, and the lengths of tube-like structures were measured with a microcomputer-assisted ImageJ. (c) G361 cells were treated with 1000 mg/ml AGE-BSA or non-glycated BSA for 24 h in the presence or absence of 2 mM AGE-aptamer or Control-aptamer. Cell proliferation levels were measured with an electron coupling reagent WST-1-based colorimetric assay. Single (*) and double asterisks (**) indicate Po0.05 and Po0.01 compared with the value of AGE alone, respectively. 
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Recent epidemiological study has shown that the increased risk of cancer deaths is lost after adjustment for glycated hemoglobin levels, while the positive association between cancer mortality and diabetes remained significant after adjusting for other risk factors. 5 These observations suggest that long-term hyperglycemic exposure may explain the link between increased cancer deaths and diabetes. Our present findings suggest that the blockade of AGE-RAGE axis by AGE-aptamer might be a novel therapeutic target of melanoma in patients with diabetes.
LIMITATIONS
Under diabetic conditions, various metabolic and hemodynamic pathways are activated. 8 To directly examine the role of AGE-RAGE axis and therapeutic implication of AGE-aptamer in melanoma growth, we used non-diabetic nude mice as a host for the present experiments, although glucose levels were usually normal and AGE-RAGE axis could not be enhanced in these animals. It would be interesting to study further whether melanoma growth is accelerated if these mice will become diabetes.
In this study, continuous intraperitoneal injection of AGEaptamer did not induce apoptotic cell death of G361 melanoma (data not shown). Combination therapy with other anti-cancer agents that sensitize melanoma cells to apoptosis might circumvent this limitation when it comes to applying AGE-aptamer as a therapeutic modality.
